8-K: Tilray Brands Reports Record FY26 Revenue and Adjusted EBITDA

Tilray Brands announced record fiscal year 2026 revenue of $915 million and record Adjusted EBITDA, driven by strong performance in its cannabis, beverage, and distribution segments, with a positive outlook for fiscal year 2027.

Summary

• Tilray Brands reported record net revenue of $915.5 million for fiscal year 2026, an 11% increase from the prior year.
• Record gross profit of $260.4 million was achieved, with an adjusted gross margin of 29%.
• Adjusted EBITDA reached $61.1 million for fiscal year 2026, an 11% increase.
• International medical cannabis revenue grew by 34% in fiscal 2026.
• The acquisition of BrewDog contributed to a pro forma global beverage platform of approximately $500 million.
• The company ended fiscal year 2026 with approximately $235 million in cash, restricted cash, and marketable securities.
• Net debt was reduced to $0.7 million.
• Guidance for fiscal year 2027 projects Adjusted EBITDA between $68 million and $75 million, indicating expected double-digit growth.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with record financial results and strong forward guidance, although the net loss and some margin pressures indicate areas for continued focus.

Positives

• Record fiscal year net revenue of $915.5 million, up 11% year-over-year.
• Record gross profit of $260.4 million.
• Record Adjusted EBITDA of $61.1 million, up 11% year-over-year.
• International medical cannabis revenue increased by 34% for the fiscal year.
• BrewDog acquisition created a global beverage platform of approximately $500 million.
• Balance sheet strengthened with approximately $235 million in cash, restricted cash, and marketable securities.
• Net debt reduced to $0.7 million.
• Positive cash flow from operations (excluding working capital) improved by 157% to approximately $18.2 million.
• Adjusted net income increased by almost 90% to $12.2 million.
• Adjusted net income per share increased to $0.11 from $0.07.

Negatives

• Gross margin for fiscal year 2026 was 28%, a decrease from 29% in the prior year.
• Beverage gross margin decreased to 36% from 39% in the prior year.
• Net loss for fiscal year 2026 was $105.2 million, compared to a net loss of $2,181.4 million in the prior year (though the prior year's loss was heavily impacted by impairments).
• Net loss per share was $1.09 for fiscal year 2026.

Risks

• Meaningful regulatory uncertainty remains regarding U.S. rescheduling developments, with ongoing legal challenges.
• The company is approaching the U.S. market opportunity with discipline and regulatory rigor, indicating potential hurdles.
• Forward-looking statements are subject to numerous risks and uncertainties, including factors outside the company's control and those not presently known.

Future Outlook

For fiscal year 2027, Tilray Brands expects to achieve Adjusted EBITDA between $68 million and $75 million, representing double-digit growth compared to fiscal year 2026. The company anticipates exceeding $1 billion in annual revenue in fiscal year 2027.

Management Comments

• "Fiscal 2026 marks an important milestone in Tilray's evolution. We didn't just deliver record revenue, record gross profit and record adjusted EBITDA, we demonstrated the strength of the diversified global platform we've been building for the last five years."
• "Today, Tilray Brands is a fundamentally different company: a global business with leadership positions across medical and adult-use cannabis, beverage, hospitality and wellness."
• "As we enter Fiscal 2027, we expect over $1 billion in annual revenue, with a stronger company than ever before."
• "The next chapter for Tilray will not be defined by one product, one market or one regulatory event. It will be defined by disciplined execution across a diversified global platform built to create enduring shareholder value."
• "We believe the opportunity ahead for Tilray Brands is greater than ever before."

Industry Context

StockSavvy.ai notes that Tilray Brands' results reflect a strategic shift towards a diversified lifestyle and consumer packaged goods company, moving beyond its core cannabis operations. The strong performance in beverage, bolstered by the BrewDog acquisition, and the continued growth in distribution, highlight a strategy to build multiple revenue streams and reduce reliance on any single market or regulatory outcome, particularly relevant in the evolving cannabis landscape.

Comparison to Industry Standards

• The 11% revenue growth for FY26 is solid, especially considering the mature nature of some of its segments and the ongoing regulatory complexities in the cannabis industry.
• The 34% increase in international medical cannabis revenue demonstrates leadership in European markets, where regulatory frameworks are more established compared to some other regions.
• The beverage segment's performance, particularly with the integration of BrewDog, positions Tilray against established global beverage players, though direct comparable metrics are not provided in the filing.
• The reduction of net debt to $0.7 million is a significant achievement, indicating strong financial discipline that is a benchmark for sustainable growth in the industry.

Legal Proceedings

• Ongoing legal challenges related to U.S. rescheduling developments.

Stakeholder Impact

• Shareholders: Positive impact from record revenue, EBITDA, and strong FY27 guidance, alongside a strengthened balance sheet and reduced debt.
• Employees: Continued focus on disciplined execution and growth may lead to stability and potential opportunities.
• Customers: Expansion of medical cannabis access in Europe and growth in beverage offerings may benefit consumers.
• Suppliers: Increased revenue and operational scale could lead to sustained business relationships.

Next Steps

• Continue to focus on disciplined execution across a diversified global platform.
• Invest in strategic growth opportunities.
• Drive long-term shareholder value.
• Further develop the U.S. Tilray Medical platform focused on research, education, cannabinoid-based medicine development, patients, and compliant medical cannabis access.
• Leverage the global beverage platform for growth and value creation.

Key Dates

Recommendation

The company has demonstrated strong execution with record results and positive future guidance, particularly in diversifying its business segments. However, the continued net loss, albeit reduced, and the inherent regulatory uncertainties in the cannabis sector warrant a cautious approach. A 'hold' recommendation reflects the balance between positive operational performance and ongoing market risks.

Keywords

Tilray Brands, Cannabis, Beverage, Financial Results, Adjusted EBITDA, Revenue, BrewDog, Medical Cannabis